PF-Atlas › Clinical Trials › NCT06717100

Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone and Nintedanib

Nintedanib 150 MG [Ofev] · Phase 1

Registry ID
NCT06717100
Phase
Phase 1
Status
Completed
Drug / intervention
Nintedanib 150 MG [Ofev]
Sponsor
PureTech
Start
2024-12-17
Enrollment
24
Locations
1

About this trial

This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .

View NCT06717100 on ClinicalTrials.gov →

Explore related

All Nintedanib 150 MG [Ofev] trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT06717100 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.